See What HealthDay Can Do For You
Contact Us

FDA Approves New Version of OTC Primatene Mist

Primatene Mist approved to provide temporary relief for symptoms of mild, intermittent asthma

asthma inhaler

THURSDAY, Nov. 8, 2018 (HealthDay News) -- A new version of an over-the-counter asthma inhaler that was taken off the market in 2011 has been approved by the U.S. Food and Drug Administration.

U.S. sales of Primatene Mist were halted because it contained chlorofluorocarbon propellants, which deplete the ozone layer. The new version contains hydrofluoroalkane propellants, which are permitted under international and U.S. law. Prescription inhalers also use hydrofluoroalkane propellants.

Primatene Mist is the only nonprescription metered-dose inhaler available in the United States and is approved to provide temporary relief for symptoms of mild, intermittent asthma, the FDA said. Patients with severe asthma should not rely on this inhaler, it warned.

Primatene Mist is approved only for patients who have been diagnosed with asthma by a health care provider and is not a replacement for prescription asthma treatments, the FDA said.

More Information

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.